M. Tajsić

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial

Stefan Störk, Sandra Prescher, Christian Butter, 2018, The Lancet.

Is 24/7 remote patient management in heart failure necessary? Results of the telemedical emergency service used in the TIM‐HF and in the TIM‐HF2 trials

S. Winkler, F. Koehler, K. Koehler, 2021, ESC heart failure.

Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome - The WilCop study.

K. Stangl, K. Huber, H. Dreger, 2018, International Journal of Cardiology.

Gender-based differences of copeptin alone or combined with troponin for early rule-out of non-ST-elevation myocardial infarction.

K. Huber, B. Jäger, T. Andric, 2020, The American journal of emergency medicine.

Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study

S. Blankenberg, K. Huber, H. Katus, 2014, European heart journal.

Biomarkers in acute coronary artery disease

K. Huber, J. Wojta, M. Freynhofer, 2012, Wiener Medizinische Wochenschrift.

Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial

S. Winkler, S. Anker, F. Koehler, 2018, The Lancet.

Copeptin for the differentiation of type 1 versus type 2 myocardial infarction or myocardial injury.

J. Wojta, K. Vargas, M. Tajsić, 2024, International journal of cardiology.